WALTHAM, Mass.--(BUSINESS WIRE)--Bioverativ Inc. (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, today announced the appointment of Geno J. Germano, a global biopharmaceutical industry executive with more than three decades of experience, to the company’s board of directors. This appointment brings Bioverativ’s total number of directors to six, five of whom are independent.
“Geno brings extensive experience in the biopharmaceutical industry and a record of successfully advancing innovation for patients,” said John Cox, Chief Executive Officer of Bioverativ. “We are excited to welcome Geno and look forward to working together to make a meaningful impact for people with hemophilia and other rare blood disorders.”
“With his considerable expertise leading global, biopharmaceutical organizations, Geno is an excellent addition to the board,” said Brian Posner, Chairman of the Board of Bioverativ. “The board welcomes Geno’s insights and looks forward to working with him alongside management to advance our dual commitments: creating progress where patients need it most and maximizing value over the long term on behalf of our shareholders.”
Mr. Germano most recently served as President of Intrexon Corporation, a leader in synthetic biology. He previously held the positions of Group President, Global Innovative Pharma Business, and President and General Manager, Specialty Care and Oncology at Pfizer, Inc. Prior to joining Pfizer, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals, including President of Wyeth U.S., and Johnson & Johnson.
“Bioverativ launched from a position of strength, and its world-class science, growing hemophilia franchise and hematology expertise has positioned the company well for future success,” said Mr. Germano. “I am honored to work with Bioverativ’s Board and the company’s talented management team to build toward the company’s vision of becoming a leader in the field of rare blood disorders.”
Mr. Germano is a member of Group of Fifty (G50), an executive group that seeks to promote openness among business leaders and to create economic and social progress. He also serves on the Board of Directors of Sage Therapeutics, Inc. and is on the Advisory Board of the Healthcare Businesswomen’s Association. He previously served on the Board of the Biotechnology Innovation Organization, where he chaired the International Committee and was a member of the Executive Committee. He is a Trustee of the Albany College of Pharmacy, from which he earned his bachelor’s degree in Pharmacy.
Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company’s mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @bioverativ on Twitter.